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 Introduction
Suicide is a significant public health problem and preventing suicide is a national priority 
[41]. Emerging evidence links chronic non-cancer pain to increased risk of suicide [3; 11; 
16; 18; 20; 30; 34; 37; 40]. This evidence is consistent despite significant differences in 
methods of pain assessment (pain level or diagnosis, use of clinical records), the population 
examined (clinical samples, population surveys), and the primary outcome (non-fatal 
attempt, suicide death). In most cases, the association between pain and suicide was partially 
attenuated but remains significant even after controlling for other psychiatric disorders, 
consistent with the interpretation that pain increases suicide risk above and beyond the 
association between pain and depression [5; 40].
Although these prior studies identify forms of chronic pain as markers of increased suicide 
risk, none have examined pain treatment as a potential additional indicator of risk among 
those with pain. With regard to suicide risk, the treatment of pain is a controversial topic. 
Some have expressed concern that the under-treatment of pain could place individuals with 
pain at elevated risk for suicide [20]. However, prescription opioids are being increasingly 
used in the United States to treat chronic pain [19] and it is possible that access to opioids, 
and specifically to large quantities of opioids, could increase the risk of suicide in those with 
chronic pain. Overall, the utility of opioids for chronic pain is disputed as there is little 
evidence for the efficacy of chronic opioid therapy while the potential harms of opioid use 
increase in a dose-response manner [6]. Increased risk of suicide with greater use of opioids 
is consistent with the broader suicide literature, which has consistently documented a link 
between suicide rates and access to potentially lethal means of suicide [36] as well as 
existing Department of Veterans Affairs and Department of Defense treatment guidelines 
that describe higher suicide risk as a relative contraindication for opioid therapy [9]. Prior 
work has found a dose-response relationship between opioid dose and increased risk of 
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unintentional poisoning (often called overdose) [2; 10]. Yet, a recent study of Veterans 
Health Affairs (VHA) patients indicated that most suicides involve firearms, and the 
proportion of suicides that involve overdose is not noticeably different in those patients with 
a diagnosed pain condition relative to those without a pain condition [16]. Importantly, in 
those patients with a diagnosed pain condition, increased opioid doses could also be a 
marker for greater pain severity or poorly controlled pain, as opioid doses are typically 
increased when lower doses and other treatment options have failed to provide adequate pain 
management. Thus, a link between increased opioid dose and suicide could be seen even if 
no causal link exists between the opioid dose and suicide risk given the association of pain 
severity with suicide risk [17].
The present study was designed to examine opioid dose as a potential marker for increased 
risk for suicide by investigating the association between opioid regimen and risk of suicide 
mortality among VHA patients with chronic pain who received an opioid.
 Methods
 Study Population
This study used a case-cohort design [31], drawing from the base population of all VHA 
patients for fiscal years (FYs) 2004–2005 nationally. For each of the two study years, a 5% 
random sample of patients was drawn, irrespective of case status. Cases were all FY04-
FY05 VHA patients who died by suicide before the end of FY09. Both cases and controls 
were further restricted to all individuals with a chronic pain condition who were treated with 
opioids (see below for clarification of these categories). Individuals with indicators of 
palliative care consultations or hospice care in their VHA medical records were excluded 
(n=1926). The sample size was 123,946. This project received approval from the Ann Arbor 
VA Human Subjects Committee.
 Data Sources
As part of ongoing VA suicide monitoring and evaluation activities, data from the VA 
National Patient Care Database (NPCD) were linked to outpatient prescription medication 
data from the VHA’s Pharmacy Benefits Management Services and VA search results from 
the Centers for Disease Control and Prevention’s National Death Index (NDI). The NPCD 
data were used to identify all individuals who utilized any services in FY04 or FY05 and 
they include information on treatment utilization, demographic characteristics and clinical 
diagnoses for all treatment contacts of patients seen anywhere in the VHA. The NDI 
contains information on date and cause of death.
 Suicide mortality
The process for ascertaining death from suicide is described more comprehensively 
elsewhere [see [14; 25]]. Briefly, for all individuals who utilized VHA services in FY04-
FY05, VHA services use was examined in FY10. NDI searches were conducted for all 
individuals who received VHA services in FY04-FY05, were alive at the start of FY04, and 
did not have VHA service use in FY10 (which would indicate survival through the end of 
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the study period). In instances where the NDI search yielded multiple potential matches, 
Sohn and colleagues’ [39] procedures were utilized to identify the best match.
 Measures
 Primary outcomes—Suicide mortality was based on deaths classified by the 
International Classification of Diseases-10 (ICD-10) codes X60-X84 and Y87.0 [44] in the 
NDI; intentional overdose was identified by ICD-10 codes X60-X69.
 Predictors—This study focused on maximum prescribed morphine-equivalent daily 
opioid dose and opioid fill type as the primary predictors of interest. Morphine-equivalent 
doses were calculated for codeine, morphine, oxycodone, hydrocodone, oxymorphone, and 
hydromorphone using established methods [2; 12; 32]. The present analyses did not examine 
synthetic opioids (which include buprenorphine) or methadone. This was done in order to 
focus on agents used to treat chronic pain, instead of the treatment of opioid dependence. In 
addition, there is little consensus on the best methods to use to calculate morphine equivalent 
dose for methadone. This creates the potential to over- or under-estimate the relationship 
between overall opioid dosage and suicide because methadone usage is known to be 
associated with overdose risk. The specific formula for calculating morphine equivalent dose 
is provided as a footnote at the bottom of Table 2. An as-prescribed approach was used to 
measure maximum daily dose [42]. The daily doses of all prescription fills that covered that 
particular day were summed to calculate a total maximum daily dose for each day of the 
study observation period. The specific daily dose for each fill was determined by dividing 
the total morphine-equivalent milligrams dispensed in that fill by the number of days 
supplied. Maximum morphine equivalent daily opioid dose was modeled as time-varying 
and recoded into categories: 0 mg, 1 to <20 mg/d, 20 to <50mg/d, 50 to < 100mg/d, and 
100+mg/d [2; 10]. These dosage categories were chosen to allow for comparison to other 
published work on unintentional overdose [2] as well recent recommendations that caution 
against prescribing more than 90–100mg/d [26]. In order to avoid double-counting dosage, 
opioid fills that appeared to be continuations of the same treatment plan (i.e., were the same 
opioid formulation and dosage) were assumed to not start until the end of the days’ supply 
of the prior fill. Also consistent with the Bohnert paper [26], for each day that an individual 
had at least one opioid prescription, a 3-level time varying indicator of opioid fill type was 
calculated to reflect schedule, with the categories of: only regularly scheduled opioids; only 
PRN opioids; or both a regularly scheduled opioid and PRN opioid prescriptions.
 Other covariates—Pain and other physical conditions were:, headache (339.x,346.x,
307.81,784.0,350.2), neuropathy (337.0,337.1,355.x,356.x,357.x, 377.x), chronic pain 
(338.0,338.2,338.4,354.4, 355.71,354.0, 355.5,710.x-729.x, 731.x-738.x), acute pain 
(800.x-959.x,338.1), chronic obstructive pulmonary disease (COPD), cardiovascular disease 
(CVD), and sleep apnea (250.x,272.0,272.1,272.2,272.3,272.4,278.00,278.01,401.x-405.x,
410.x-414.x,430.x-438.x,491.x,492.x,494.x,496.x,780.51,780.53,780.57,783.1), and cancer 
(140.x-239.x,338.3). Psychiatric conditions were: depression, bipolar disorder, mood NOS 
(293.83,296.2,296.3,296.90,296.99, 298.0,300.4,301.12, 309.0,309.1,311, 296.0–296.1, 
296.4–296.8), psychotic disorders (295.0–295.4,295.6–295.9,297.0–297.3,297.8–
298.4,298.8,298.9), substance use disorders (291,292,303.0,303.9,304.0–304.9,305.0,305.2–
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305.9), Post-Traumatic Stress Disorder (309.81), and other anxiety disorders 
(300.00,300.01,300.02,300.09,300.10,300.20–300.23,300.29). The Charlson Comorbidity 
Index [4; 33] was used to measure medical comorbidity based on ICD-9-CM codes and 
recoded as 0, 1, or ≥2 conditions. Age in years at the start of FY04 was divided into the 
following categories to match existing research on suicide risk in Veterans [25]: 18–29, 30–
39, 40–49, 50–59, 60–69, and 70 years or older. Race (coded as White, Black, and Other/
missing) and Hispanic ethnicity were also included in the analyses.
 Analyses
The suicide rates associated with specific opioid prescribing characteristics (dose and 
schedule) were estimated by accounting for the case-cohort design. To do so, we first 
calculated the cumulative number of suicide deaths that occurred under each of the opioid 
prescribing conditions (e.g., number of patients who died while prescribed a particular 
dose). The denominator for each rate was calculated in two steps. First, we summed the 
person-years contributed by the random sample under each opioid prescribing characteristic. 
These values were then multiplied by the inverse of sampling fraction (the proportion of all 
VHA patients for FY04 or FY05 who were selected under the random sampling scheme) in 
order to provide an estimate of the person-time for each opioid treatment characteristic that 
would have been observed for the entire population, had pharmacy data for the entire 
population been available. This method was necessary because the cases were drawn from 
the entire population and not just the random sample. Consequently, all rates are estimated 
rather than directly observed. Cox proportional hazards models were used to examine the 
relationship between opioid regimen and suicide death adjusting for demographic and 
clinical characteristics. All multivariable models were restricted to periods of time when 
individuals were prescribed at least one opioid. A risk-sets approach and a robust variance 
estimator were used for the multivariable modeling [22].
 Results
A total of 2,601 patients died by suicide during the observation period; 1,669 (64.2%) of 
suicides were due to firearms, 532 (20.5%) to an overdose, and 252 to strangulation (9.7%). 
Table 1 describes differences between those who died by suicide and those who did not.
The rates of suicide per 100,000 person years by any mechanism were 44.4 (95% confidence 
interval (CI) 42.3, 46.5) when the maximum prescribed dose was 0 mg and 105.0 (95% CI 
88.4, 123.1) when the maximum dose prescribed was 100+mg/d (see Table 2). Estimated 
unadjusted rates of suicide per 100,000 person-years were 67.9 (95% CI 60.4, 76.0) during 
time periods with only regularly scheduled doses, 54.9 (95% CI 50.1, 59.9) with only PRN 
doses, and 90.1 (95% CI 73.7, 108.2) during periods with both regularly scheduled and PRN 
doses. Rates of suicide by intentional overdose ranged from 8.2 (95% CI 7.3, 9.1) per 
100,000 person years when the maximum prescribed dose was 0 mg to 27.8 (95% CI 19.5, 
37.4) per 100,000 person years when maximum prescribed dose was 100 milligrams or 
more. By fill type, the rates per 100,000 person years were 17.5 (95% CI 13.8, 21.7) for time 
periods with only regularly scheduled doses, 12.8 (95% CI 10.6, 15.3) with only PRN doses, 
and 24.0 (95% CI 16.0, 33.7) during periods with both regular and PRN doses.
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In models examining the association of opioid regimen with risk of suicide, a relationship 
was observed with opioid dose. A prescribed dose of 1 to <20 mg/d was the reference group 
and the estimated adjusted hazard ratios were: 1.48 (95% CI 1.25, 1.75) for 20 to <50mg/d, 
1.69 (95% CI 1.33, 2.14) for 50 to <100mg/d, and 2.15 (95% CI 1.64, 2.81) for 100+mg/d. 
Opioid schedule was not significantly associated with suicide risk in the adjusted models. 
Similarly, for models specifically examining intentional overdose, with 1 to <20mg/d as the 
reference group, the adjusted hazard ratios were: 1.59 (95% CI 1.12, 2.27) for 20 to 
<50mg/d, 1.74 (95% CI 1.09, 2.76) for 50 to <100mg/d, and 2.09 (95% CI 1.22, 3.56) for 
100+mg/d. Opioid fill type was not significantly associated with intentional overdose in the 
adjusted models.
 Supplementary Analyses
An additional analysis examined the relationship between total opioid dose and suicide 
when tramadol was included in the calculation of total opioid dose. The results of this 
analysis indicate that the association between opioid dose and suicide was still present when 
including tramadol, although to a somewhat lesser magnitude than in the primary analyses. 
Specifically, adjusted hazard ratios were 1.45 (95% CI 1.21, 1.72) for 20 to <50mg/d, 1.47 
(95% CI 1.17, 1.84) for 50 to <100mg/d, and 1.69 (95% CI 1.36, 2.10) for 100+mg/d.
To examine the potential connection between suicide and other medications used to treat 
pain, we conducted additional analyses testing for associations between acetaminophen dose 
and regimen and suicide risk. Estimated unadjusted rates of suicide per 100,000 person-
years were 45.4 (95% CI 40.4, 50.8) when the maximum prescribed dose was 0 mg and 63.0 
(95% CI 36.7, 96.3) when the maximum dose prescribed was 3000+mg/d. Suicide rates were 
53.8 (95% CI 40.5, 68.9) during time periods with only regularly scheduled doses, and 54.8 
(95% CI 33.9, 80.5) with only PRN doses.
 Discussion
This study examined the association between prescribed opioid dose and suicide in a 
national sample of VHA patients with a chronic non-cancer pain condition who received 
opioid therapy. Increased dose of opioids was found to be a marker of increased suicide risk, 
even when relevant demographic and clinical factors were statistically controlled. The type 
of opioid dosing schedule did not significantly affect suicide risk after accounting for other 
factors. Similar to the general US population and other large studies of VHA patients [16; 
35], the vast majority of suicides involved firearms, with overdose accounting for 
approximately 15–20% of all suicides. The strength of association between opioid dose and 
suicide was essentially the same when looking specifically at overdose-related suicides 
compared to all suicides. In addition, in supplementary analyses, there was no significant 
association between acetaminophen dose and regimen and suicide risk, suggesting that the 
observed effects may be specific to opioids. Overall, these findings highlight a potential link 
between opioid dose and suicide in those with pain but also suggest that this relationship is 
likely more complicated than an increase in access to opioids leading to an increase in 
intentional overdoses.
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The use of prescription opioids as a frontline treatment for chronic pain has increased 
sharply in the past decade [19]. This has corresponded with a number of adverse outcomes, 
including increases in the prevalence of opioid misuse and unintentional overdose [28; 29; 
43]. Prior work has described a dose-response association between daily opioid dose and 
risk of unintentional overdose [2; 10; 13]. The present study documents a similar 
relationship between daily opioid dose and suicide risk. However, the magnitude of the 
association with suicide is somewhat lower than what has been described for unintentional 
opioid overdose in a similar sample of VHA patients [2]. Given the observational design of 
the present study, it is not known whether suicide should be conceptualized as an adverse 
outcome of opioid use or if opioid dose is merely a marker of increased pain duration and/or 
severity, or suboptimal pain management efforts.
Prior work focused on suicide risk in those with chronic pain has highlighted the potential 
importance of examining the impact of pain treatment [40]. However, to the best of our 
knowledge, this has not been done previously. Although many possible explanations exist 
for why opioids may relate to suicide risk, two potential reasons for this relationship are that 
either: (1) under-treatment of pain in those with chronic pain conditions could increase the 
risk of suicide [20] or (2) providing opioids to those with pain could increase the access to a 
potentially lethal means of suicide in a group known to have high rates of co-occurring 
psychiatric disorders. The finding that suicide risk increased along with opioid dose might 
seem to counter the hypothesis that under-treatment of pain increases suicide risk. However, 
it is important to note that, in many cases, increased opioid use may not result in significant 
long-term reductions in pain or improvements in functioning [23]. Moreover, greater clinical 
reliance on opioid therapy may be a marker for poor access to other effective pain 
management options (e.g., cognitive behavioral therapies, physical therapy, multidisciplinary 
pain treatment). Clinicians and patients faced with unmanaged pain and no access to non-
pharmacological treatment options may choose to increase opioid dose due to lack of other 
options. In addition, prolonged exposure to opioids can induce hyperalgesia, or an over-
response to painful stimuli [7] and others have hypothesized that increased sensitivity to pain 
may explain the association between opioid use and prior suicidal behaviors [27]. However, 
directly testing the impact of poorer access to treatment and/or greater sensitivity is not 
possible with the current data.
This study cannot answer the question of whether increased access to opioids increases 
suicide risk by providing individuals with access to a potentially lethal means of suicide. 
Yet, the fact that a stronger relationship was not found for suicide by overdose suggests that 
the relationship between opioids and suicide may be more complicated than just the 
increased use of opioids as a method for suicide. This is consistent with other work, which 
has found that the vast majority of suicides among those with substance use disorders do not 
involve overdose [15]. One alternative explanation for a direct association between opioid 
use and suicide is that the disinhibiting effects of higher doses of prescription opioids could 
increase the likelihood that individuals with suicidal thoughts or plans could act on these 
impulses [8]. It is also possible that the observed association between higher opioid dose and 
suicide may not be due to the direct impact of opioids but may, instead, be due to the 
characteristics of the individuals who receive elevated opioid doses. This confounding or 
selection effect could reflect the impact of the presence of specific psychiatric or pain 
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conditions, poorer sleep or functioning in those who receive higher opioid doses compared 
to lower doses. Other psychological or contextual factors such as hopelessness, increased 
stigma or frustration with the quality of one’s care cannot be measured within the present 
data and may explain why those who receive more opioids are more likely to die by suicide. 
In the present study, associations between opioid dose and suicide remained significant in 
the presence of specific psychiatric conditions, which argues against psychopathology as an 
alternative explanation for the effect of opioid dose on suicide. However, it is likely that 
many psychiatric and substance use disorders were not detected during usual care and 
residual confounding could still partially or fully account for the observed associations 
between opioids and suicide.
Another possibility is that the prescription of high doses of opioids is a marker of help-
seeking for pain that exceeds the patient’s ability to cope. The difficulties of attributing 
effects in suicide to specific medications in observational research are not unique to opioids 
and others have concluded that no observational study can fully account for potential 
confounders [21]. Even if the observed increase in suicide risk is not directly caused by 
opioid dose, the present findings highlight the importance of greater monitoring and 
treatment for suicide risk among those receiving higher opioid doses. Also, to the extent that 
higher opioid doses reflect longer duration of pain, greater pain severity, and/or ineffective 
pain treatment, results point to the importance of optimizing pain management strategies 
among those with severe and/or uncontrolled pain.
This study has additional limitations worth noting. Individuals in this study are VHA 
patients and the findings may not generalize outside the VHA. Suicide rates in the VHA are 
higher than age- and gender-matched individuals in the US population and risk factors [1; 
24], such as pain and opioid dose, may also function differently in the VHA. Also, the fact 
that all individuals in this study were receiving care from a large integrated healthcare 
system could influence the ways in which aspects of care relate to suicide risk. The analyses 
also did not account for other CNS depressants, duration of prior opioid prescription, or 
recent changes in opioid dose. In addition, the as-prescribed approach utilized to model the 
association between opioid dose and suicide only examines the dose of the medication 
provided, not the amount consumed. It is likely that some individuals deviated from their 
prescription [38] and this is not captured in these analyses. In addition, sample sizes for 
some subgroups (e.g., opioid dose of 100mg+) were relatively low, resulting in wider 
confidence intervals for point estimates of suicide rates. The present models did not include 
duration or severity of chronic pain, and it is possible that longer pain duration and/or 
greater pain severity may predict both higher opioid dose and increased suicide risk.
Even with these limitations, this study is the first to examine the link between opioid dose 
and suicide mortality in those with chronic pain. The present findings indicate that greater 
opioid dose is a marker for increased suicide risk. In addition, the present results indicate 
that this relationship is not limited to suicide by overdose but that opioid dose is associated 
with a broader array of suicide methods. A high priority for future research is the assessment 
of the common and unique effects of opioid use and pain chronicity and/or severity on 
suicide risk. Testing for longitudinal associations between opioid use, pain duration and 
severity, and surrogate endpoints (e.g., suicidal ideation) might better illuminate the 
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mechanisms whereby opioid use may lead to greater suicide risk. In addition, identification 
of subgroups that may be more or less susceptible to opioid-related adverse outcomes will 
inform clinical efforts to develop optimal pain management strategies that do not carry 
added risk for suicide. Finally, although the present design cannot determine the causes of 
the link between opioids and suicide, clinicians treating patients with pain who are receiving 
higher doses of opioids should be aware of the increased suicide risk and monitor suicidal 
thoughts and plans in these patients. It is possible that a greater attention to suicide risk, 
combined with increased psychiatric treatment and utilization of other pain management 
strategies, might help to mitigate the increased risk for suicide among pain patients receiving 
higher doses of opioids.
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Table 1
Patient characteristics (N=123,946).
Suicide Deaths Random Sample p-value
(N=2601) (N=121,345)
N (%) (N%)
Demographics
Male 2499 (96.1) 112,453 (92.7) <.0001
Female 102 (3.9) 8892 (7.3)
Age <.0001
 18–29 59 (2.3) 3015 (2.5)
 30–39 160 (6.2) 6841 (5.6)
 40–49 556 (21.4) 19,311 (15.9)
 50–59 819 (31.5) 40,209 (33.1)
 60–69 412 (15.8) 22,687 (18.7)
 70+ 595 (22.9) 29,282 (24.1)
Race
 White 2171 (83.5) 88,698 (73.1) <.0001
 Black 121 (4.7) 20,322 (16.8)
 Other/Missing 309 (11.9) 12,325 (10.2)
Hispanic Ethnicity 64 (2.5) 5689 (4.7) <.0001
Physical Conditions and Pain
 COPD/CVD/Sleep Apnea Dx 1954 (75.1) 99,251 (81.8) <.0001
 Chronic Pain Dx 2472 (95.0) 116,006 (95.6) 0.169
 Headache Dx 286 (11.0) 11,047 (9.1) 0.001
 Injury/Acute Pain Dx 572 (22.0) 24,991 (20.6) 0.082
 Neuropathy Dx 274 (10.5) 13,704 (11.3) 0.226
 Cancer Dx 530 (20.4) 27,220 (22.4) .0129
Psychiatric Conditions
 Depression, Bipolar, mood NOS Dx 1154 (44.4) 32,698 (27.0) <.0001
 Other Anxiety Dx 423 (16.3) 11,082 (9.1) <.0001
 PTSD 383 (14.7) 15,338 (12.6) 0.002
 Psychotic Disorders Dx 163 (6.3) 4425 (3.7) <.0001
 Substance Use/Dependence Dx 513 (19.7) 12,252 (10.1) <.0001
Charlson Comorbidity Index Score
 0 1160 (44.6) 49,883 (41.1) .001
 1 631 (24.3) 29,839 (24.6)
 2+ 810 (31.1) 41,623 (34.3)
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Table 2
Unadjusted rates of suicide deaths by opioid dose and fill type.
Deaths (n) Person-Years Rate/100,000 PY(95% CI)
Suicide, Any Mechanism
Prescribed Daily Opioid Dose
 0 1716 3,862,873 44.4 (42.3, 46.5)
 1 to < 20 mg/d* 218 508,852 42.8 (37.3, 48.7)
 20 to < 50 mg/d* 395 618,533 63.9 (57.7, 70.3)
 50 to < 100 mg/d* 132 174,839 75.5 (63.2, 88.9)
 100+ mg/d 140 133,284 105.0 (88.4, 123.1)
Fill Types
 Regularly Scheduled Only 291 428,362 67.9 (60.4, 76.0)
 PRN Only 489 890,666 54.9 (50.1, 59.9)
 Simultaneous PRN and Regularly Scheduled 105 116,480 90.1 (73.7, 108.2)
Intentional Overdose, Any Substance
Prescribed Daily Opioid Dose
 0 315 3,862,873 8.2 (7.3, 9.1)
 1 to < 20 mg/d* 47 508,852 9.2 (6.8, 12.1)
 20 to < 50 mg/d* 99 618,533 16.0 (13.0, 19.3)
 50 to < 100 mg/d* 34 174,839 19.4 (13.5, 26.5)
 100+ mg/d 37 133,284 27.8 (19.5, 37.4)
Fill Types
 Regularly Scheduled Only 75 428,362 17.5 (13.8, 21.7)
 PRN Only 114 890,666 12.8 (10.6, 15.3)
 Both Regularly Scheduled and PRN 28 116,480 24.0 (16.0, 33.7)
*
The following formula was used to calculate morphine equivalent doses: dose = (size_mg)*(tl_qty/day_supply); Conversion factors multiplied by 
dose to get morphine equivalencies: CODEINE =.15; HYDROCODONE=1; HYDROMORPHONE=4; OXYCODONE=1.5;OXYMORPHONE=.
56; HYDROMORPHONE (injected)=16;MORPHINE (injected)=3
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Table 3
Cox proportional hazards models of risk of death by suicide.
Suicide, Any Mechanism Intentional Overdose
Treatment and Patient Characteristics HR (95% CI) HR (95% CI)
Prescribed Daily Opioid Dose
 1 to < 20 mg/d 1.00 1.00
 20 to < 50 mg/d 1.48 (1.25, 1.75) 1.59 (1.12, 2.27)
 50 to < 100 mg/d 1.69 (1.33, 2.14) 1.74 (1.09, 2.76)
 100+ mg/d 2.15 (1.64, 2.81) 2.09 (1.22, 3.56)
Opioid Fill Type
 Regularly Scheduled Only 1.00 1.00
 PRN only 1.08 (0.92, 1.27) 1.12 (0.83, 1.52)
 Simultaneous PRN and Regularly Scheduled 1.07 (0.82, 1.41) 1.10 (0.64, 1.87)
Physical Conditions and Pain
 COPD/CVD/Sleep Apnea Dx 0.76 (0.63, 0.90) 0.58 (0.43, 0.79)
 Chronic Pain Dx 0.76 (0.53, 1.09) 0.83 (0.41, 1.69)
 Headache Dx 1.07 (0.86, 1.35) 1.08 (0.73, 1.60)
 Injury/Acute Pain Dx 0.98 (0.82, 1.17) 1.05 (0.76, 1.46)
 Neuropathy Dx 0.89 (0.71, 1.12) 1.20 (0.77, 1.86)
 Cancer Dx 1.16 (0.98, 1.38) 0.94 (0.64, 1.40)
Psychiatric Conditions
 Depression, Bipolar, mood NOS Dx 1.44 (1.24, 1.68) 2.40 (1.78, 3.23)
 Other Anxiety Dx 1.34 (1.11, 1.61) 1.29 (0.92, 1.81)
 PTSD 0.81 (0.66, 0.99) 0.78 (0.54, 1.13)
 Psychotic Disorders Dx 1.56 (1.15, 2.12) 2.41 (1.50, 3.87)
 Substance Use/Dependence Dx 2.04 (1.69, 2.46) 2.00 (1.44, 2.78)
Charlson Comorbidity Index Score
 0 1.00 1.00
 1 1.14 (0.96, 1.36) 1.18 (0.85, 1.64)
 2+ 1.05 (0.88, 1.26) 0.88 (0.60, 1.28)
Cancer Diagnosis 1.16 (0.98, 1.38) 0.94 (0.64, 1.40)
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Suicide, Any Mechanism Intentional Overdose
Treatment and Patient Characteristics HR (95% CI) HR (95% CI)
Demographics
 Male 2.07 (1.43, 2.99) 0.94 (0.59, 1.50)
 Age (Reference: 18–29)
  30–39 0.86 (0.47, 1.60) 1.26 (0.43, 3.72)
  40–49 0.91 (0.52, 1.60) 1.44 (0.52, 3.99)
  50–59 0.70 (0.40, 1.23) 0.84 (0.30, 2.35)
  60–69 0.81 (0.45, 1.44) 0.58 (0.19, 1.74)
  70+ 1.07 (0.60, 1.91) 0.56 (0.18, 1.75)
 Race (Reference: White)
  Black 0.27 (0.19, 0.38) 0.28 (0.14, 0.55)
  Other/Missing 0.56 (0.44, 0.73) 0.71 (0.42, 1.20)
Hispanic Ethnicity (Reference: Non-Hispanic) 0.66 (0.41, 1.06) 1.18 (0.59, 2.36)
  Ethnicity Unknown 3.52 (2.94, 4.21) 3.29 (2.23, 4.84)
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